On the second day of AFRAVIH, a Francophone international AIDS conference in Geneva, UNITAID calls on the international community to implement three urgent measures to overcome obstacles in the progress against AIDS: reduce the effect of free trade agreements, tap into fresh sources of funding, such as a financial transaction tax, and promote treatment optimization and affordability through market approaches.
In the lead up to Free Trade Agreement (FTA) discussions during the European Union-India Summit in New Delhi on 10 February, UNITAID urges both parties to ensure that access to medicines, and particularly AIDS medicines,is not hampered by trade interests via provisions that could undermine the production, registration and availability of generic medicines.
At its meeting in Paris on 12-13 December, the UNITAID Executive Board demonstrated its continued commitment to scaling up access for HIV/AIDS and malaria by allocating an extra US$ 138 million to the two diseases.
UNITAID is committed to building on 10 years of historic progress in the fight against AIDS and keep the agenda moving forward to the next level of cost-effective quality care.
Two new meta studies published in the Journal Nature, one authored by Dr. David Gems, and the second one by Drs. Auwerx and Canto, examine previous studies of red wine's ability to promote human health and longevity.
Sweet Cures of York, (UK) is achieving phenomenal sales with the company's new product – 'Diabetrose™', based on arabinose, which is the natural substance in the raw food diet that helps us mammals release the glucose from the food we eat in a sustained way.
In the lead-up to the United Nations High Level Meeting on AIDS, next week, UNITAID today releases a landmark report revealing that innovative technologies to test and monitor HIV/AIDS could soon be within reach of the world’s poorest regions.
ESTHER lance au Bénin son projet ESTHERAID, dont l’objectif est d’améliorer l’accès aux traitements antirétroviraux, dans 5 pays : Bénin, Burkina Faso, Cameroun, Mali et République Centrafricaine.
A randomised, double blind, placebo controlled efficacy and safety trial of different doses/dose regimens of FP187 compared to placebo in moderate to severe plaque psoriasis.
